Nuplazid suppresses esophageal squamous cell carcinoma growth in vitro and in vivo by targeting PAK4
Yaxing Wei, Wenjie Wu, Yanan Jiang, Hao Zhou, Yu Yin, Lili Zhao, Xiangyu Wu, Xuebo Lu, Qiang Yuan, Zitong Wang, Zigang Dong, Luyun He, Jimin Zhao, Kangdong Liu
Abstract
BACKGROUND: Due to the high recurrence and low 5-year survival rates of esophageal squamous cell carcinoma (ESCC) after treatment, the discovery of novel drugs for recurrence chemoprevention is of particular importance. METHODS: We screened the FDA-approved drug library and found that Nuplazid, an atypical antipsychotic that acts as an effective 5-HT 2 A receptor inverse agonist, could potentially exert anticancer effects in vitro and in vivo on ESCC. RESULTS: Pull-down results indicated that Nuplazid binds with p21-activated kinase 4 (PAK4), and a kinase assay showed that Nuplazid strongly suppressed PAK4 kinase activity. Moreover, Nuplazid exhibited inhibitory effects on ESCC in vivo. CONCLUSIONS: Our findings indicate that Nuplazid can suppress ESCC progression through targeting PAK4.